A Study of Distal Jejunal-release Dextrose in Obese Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-01

Study Completion Date

2024-11-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose \[Aphaia technology, AT\]) in obese participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel Composition Compared to Placebos in Obese Subjects With Weight Related Comorbidities

NCT07008456

Obese With Comorbidities Obese Patients (BMI ≥ 30 kg/m²)

RECRUITING PHASE2

A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity

NCT04010786

Overweight Obesity

COMPLETED PHASE1

A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet

NCT05429593

Healthy Volunteers

COMPLETED PHASE1

A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

NCT05761301

Type 2 Diabetes Mellitus (T2DM)

TERMINATED PHASE1/PHASE2

A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers

NCT01044108

Metabolism and Nutrition Disorder Obesity

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blind, placebo-controlled, parallel-group, phase II proof-of-concept study to be conducted in 150 adult obese male and female participants who are 18 to 70 years of age with or without one or more endocrine and/or metabolic conditions. The study aims to evaluate the efficacy and safety of distal jejunal-release dextrose (Aphaia technology, AT) in obese participants.

Participants will be randomly assigned to receive either APHD-012 (distal jejunal-release dextrose or APH-012P (a matching placebo). There will be two cohorts in the study. Participants from Cohort 1 will receive study medication once daily for 12 months (360 days), and participants from Cohort 2 will receive study medication once daily for 6 months (180 days).

Overall, 150 participants will be enrolled in the study:

* Cohort 1 (60 participants) - 6-month treatment period + 6-month maintenance treatment period
* Cohort 2 (90 participants) - 6-month treatment period

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obese

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel Assignment Randomized, double-blind, placebo-controlled, parallel-group proof-of-concept efficacy and safety study

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

APHD-012

Participants will receive a single dose of APHD-012 12 g daily, under fasting conditions prior to main daily meals for 180 days (6 months) for Cohort 2 and for 360 days (12 months) for Cohort 1.

Group Type ACTIVE_COMPARATOR

APHD-012

Intervention Type DRUG

Distal jejunal-release dextrose beads (Aphaia technology, AT)

APHD-012P

Participants will receive a single dose of APHD-012P daily, under fasting conditions prior to main daily meals for 180 days (6 months) for Cohort 2 and for 360 days (12 months) for Cohort 1.

Group Type PLACEBO_COMPARATOR

APHD-012P

Intervention Type DRUG

Distal jejunal-release placebo beads

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

APHD-012

Distal jejunal-release dextrose beads (Aphaia technology, AT)

Intervention Type DRUG

APHD-012P

Distal jejunal-release placebo beads

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Distal jejunal-release dextrose beads Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body mass index 30.0-39.9 kg/m\^2 and/or waist circumference: men \>102 cm, women \>88 cm
* Stable body weight: gain or loss in body weight ≤5 kg over last 3 months
* Obese participants with or without one or more of the following conditions:

1. NAFLD - simple steatosis based on a FibroScan CAP™ test result at screening (CAP Score ≥238 decibel-milliwatts (dB/m) (Steatosis Grades 1-3) with no or mild fibrosis (F0-F1 fibrosis Score)
2. NASH - steatohepatitis based on FibroScan fibrosis Score at screening (≥7.5 kPa and \<14 kPa (Stage F2-F3)
3. Confirmed medical history of metabolic syndrome
4. Homeostatic Model Assessment of Insulin Resistance (HOMA IR) Score ≥2
5. Confirmed medical history of type 2 diabetes mellitus (T2DM) diagnosis or HbA1c ≥7.0 and \<11 (based on screening values)
6. High total cholesterol ≥240 mg/dL (based on screening values)
7. Hypertension (participants with Stage 1 hypertension (systolic blood pressure \[SBP\] ≥130 mmHg \<180 mmHg, diastolic blood pressure \[DBP\] ≥80 mmHg \<110 mmHg) (based on screening values)
* If on medication to manage endocrine/metabolic conditions, must be on stable doses of medication ≥3 months prior to screening:

1. Participants with T2DM may be treated with either diet and exercise alone, metformin, sulphonylurea, thiazolidinediones, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and bromocriptine quick-release (QR) as single agents or combination therapy.
2. As lipid-lowering medication participants may be treated with statins and fibrates, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, ezetimibe, or supplements like omega-3-fatty acids.
3. As antihypertensive medication participants may be treated with beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II-inhibitors, diuretics, or calcium channel blockers.
* Normal GI function, or abnormalities which the clinical investigator does not consider a disqualification for participation in the study

Exclusion Criteria

* Incomplete Coronavirus Disease of 2019 (COVID-19) vaccination
* Treatment with weight loss medications in the past 3 months
* Proven history of bulimia or anorexia nervosa
* Treatment with injectable antidiabetic medications in the last 3 months (e.g. Glucagon-like peptide-1 \[GLP-1\] receptor agonists, insulin)
* Treatment with dipeptidyl peptidase-4 inhibitors in the last 3 months
* NASH with cirrhosis (fibrosis Score=F4 (≥14 kPa) as determined by screening FibroScan
* Confirmed medical history of liver cirrhosis, cholestatic disease, alcohol-related liver disease
* Type 1 diabetes mellitus, HbA1c ≥11, fasting plasma glucose levels ≥270 mg/dL
* Proliferative retinopathy or maculopathy
* Abnormal liver function tests:

1. Transaminases:

* Alanine transaminase (ALT)/aspartate aminotransferase (AST) ≥5 x upper limit of normal (ULN) for participants with NAFLD or NASH (as determined by screening FibroScan)
* ALT/AST ≥2.5 x ULN for participants without NAFLD or NASH (as determined by screening FibroScan)
2. Alkaline phosphatase (ALK) ≥2.5 x ULN
3. Total bilirubin ≥2 x ULN
* Stage 4 hypertension (SBP ≥180, DBP ≥110)
* History or presence of any uncontrolled cardiovascular, pulmonary, hepatobiliary, renal, hematologic, gastrointestinal, endocrinologic, immunologic, dermatologic, neurological, psychiatric, metabolic, musculoskeletal, or malignant disease (except conditions accepted for inclusion) which the clinical investigator does not consider a disqualification for participation in the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No